Background: To assess the outcomes of ivermectin in ambulatory and hospitalized patients with COVID-19. Methods: Five databases and websites for preprints were searched until January 2021 for randomized controlled trials (RCTs) and retrospective cohorts assessing ivermectin versus control in ambulatory and hospitalized participants. The primary outcome was overall mortality. Secondary outcome was recovered patients. For meta-analysis, random-effects and inverse variance meta-analyses with logarithmic transformation were performed. ROBINS-I for cohort studies, and the Cochrane Risk of Bias 2.0 tool for trials were used. The strength of evidence was assessed using GRADE. Results: After the selection, twelve studies (five retrospective cohort studies, six randomized clinical trials and one case series), were included. In total, 7412 participants were reported, the mean age was 47.5 (SD 9.5) years, and 4283 (58%) were male. Ivermectin was not associated with reduced mortality (logRR: 0.89, 95% CI 0.09 to 1.70, p = 0.04, I 2 = 84.7%), or reduced patient recovery (logRR 5.52, 95% CI -24.36 to 35.4, p = 0.51, I 2 = 92.6%). All studies had a high risk of bias, and showed a very low certainty of the evidence. Conclusions: There insufficient certainty and quality of evidence to recommend the use of ivermectin to prevent or treat ambulatory or hospitalized patients with COVID-19.
Xanthogranulomatous endometritis (XGE) or histiocytic endometritis is a chronic inflammatory pathology of rare presentation, characterized by an exaggerated inflammatory infiltrate that can mimic an endometrial carcinoma. We report two cases of this disease, one of them with a classic presentation of endometritis and the other one with a severe compromise in which the clinical presentation and imaging findings suggested a possible endometrial carcinoma. Knowledge of this unusual and rare pathology, including its etiopathogenesis, is important since it can be included in the differential diagnosis of endometrial carcinoma and, therefore, whenever it is found, to avoid excessive treatment.
Endometriosis is a chronic, estrogen-dependent inflammatory disease influenced by complex neuroimmune interactions and pain chronification mechanisms. Modern medical management is increasingly guided by a deeper understanding of neuroinflammation, peripheral and central sensitization, and immune dysregulation, moving beyond traditional hormonal suppression. This chapter will synthesize the latest evidence on precision medicine approaches, integrating pain phenotyping, molecular and inflammatory biomarkers, and mechanisms of treatment resistance. It will explore targeted pharmacologic strategies, including neuromodulators, selective progesterone receptor modulators, immunomodulatory and anti-fibrotic agents, as well as innovative non-hormonal therapies under investigation. Additionally, it will highlight research gaps and opportunities for translational applications. The aim is to provide a rigorous, mechanism-based framework for individualized, effective, and biologically informed medical treatment of endometriosis.
Objetivo: El presente estudio se centró en determinar si la diferencia de hemoglobina del tercer y el primer trimestre de gestación mayor de – 1 (Delta de hemoglobina disminuido) es un factor de riesgo para el bajo peso al nacer en recién nacidos a término en el Hospital Belén de Trujillo. Material y métodos: Estudio de cohorte histórica. Se realizó un estudio de cohorte retrospectiva donde se incluyeron 218 neonatos, de acuerdo con los criterios de selección, los cuales fueron divididos en dos grupos: pacientes con delta de hemoglobina materna disminuida y no disminuida: aplicando el riesgo relativo y el test estadístico de chi-cuadrado. Resultados: La frecuencia de neonatos con bajo peso al nacer en mujeres embarazadas con delta de hemoglobina disminuida fue de 32/109 = 29 %; la frecuencia de bajo peso al nacer en las mujeres embarazadas con delta de hemoglobina no disminuida fue de 18/109 = 17 %. La delta de hemoglobina materna disminuida es un factor de riesgo para el bajo peso al nacer con un riesgo relativo de 1.78 [IC: 95 % (1.45 – 3.56) p < 0.05]. Conclusiones: La delta de hemoglobina materna disminuida es un factor de riesgo para el bajo peso al nacer en recién nacidos a término en el Hospital Belén de Trujillo.